Innovation Pharmaceuticals Signs Agreement for Advanced Oral Tablet Technology in Treating Inflammatory Bowel Disease

    NEXT STORY
    Global Point-of-Care Diagnostics, Health & Biosensors Conference 2019: POC Testing Landscape, Novel Technologies to Regulatory Approval (San Diego, CA, United States – October 7-9, 2019)
    PREV STORY
    Three-Year Clinical Trial Results Support ILUVIEN® Launch in Europe for the Prevention of Relapse in Recurrent Non-Infectious Uveitis Affecting the Posterior Segment
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE “TRANSPARENCY LAW”)

    REGULATED INFORMATION GHENT, Belgium, 28 March 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] ...

    author_avatar
    NASDAQ Market News

    XOMA Acquires Royalty Interest Position from Agenus on Seven Assets Being Developed by Merck and Incyte

    EMERYVILLE, Calif., Sept. 21, 2018 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today ...

    author_avatar
    NASDAQ Market News

    BioXcel Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update

    author_avatar
    NASDAQ Market News